CER Daily Newsfeed

The Comparative Effectiveness Research Daily Newsfeed®, known for short as the CER Daily Newsfeed®, offers the latest news, research and related information on comparative effectiveness research, real-world data and evidence, value assessment and other important health care topics. 

News from Monday, September 20, 2021

Articles

CDC Study Finds Waning Immunity in Pfizer-BioNTech Vaccine Recipients after Four Months

(9/17, Brian Buntz, Drug Discovery & Development) reports “...The CDC also concluded that, from March 11 to August 15, the Moderna vaccine was 93% effective. The Pfizer-BioNTech and Janssen vaccines had lower effectiveness rates of 88% and 71%, respectively. The research also found that post-vaccination anti-spike IgG and anti-RBD IgG antibodies levels were ‘significantly lower’ for Janssen vaccine recipients than those who received mRNA vaccines.” Full

 

Video: Registries Play Key Role in Real-World Evidence Studies

(9/18, Daniel Barthelmes, MD, PhD, Ocular Surgery News) “In this video perspective from the virtual Euretina congress, Daniel Barthelmes, MD, PhD, speaks about the key role of registries in investigating treatment outcomes in real-world clinical practice.” View Video

 

How Specialty Pharmacies Connect the Dots for Patient-Centered Care

(9/20, Health Payer Intelligence) comments “...Specialty pharmacies play a pivotal role in ensuring patients have access to the proper medications and resources necessary to stay adherent. They have evolved to handle the complexity and costs of specialty pharmaceuticals while at the same time managing reimbursement and providing individualized clinical support to patients. Within the concept of patient-centered care, these pharmacies function as the lynchpin bringing together manufacturers, providers, payers, and caregivers to streamline a process aimed at achieving optimal health outcomes for patients.” Full

 

Unlocking Orphan Pricing In France

(9/20, Francesca Bruce, Pink Sheet) reports “...Companies should not assume that addressing an unmet meet will guarantee a high price, warn the authors of a recent analysis of non-oncology orphan drug pricing in France. Low patient numbers and methodologically robust clinical data that stands a better chance of securing a good health technology appraisal outcome can lead to higher prices, finds the study. Charles River Associates, the global consultancy company behind the study, also warned that ‘there should be no presumption that high prices are possible purely because of unmet need in a rare disease indication.’” Paid Subscription Required

Reports

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

September 17, 2021

CDC